Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APMNYSE:DNANASDAQ:SLSNASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$0.96+4.2%$0.98$0.46▼$7.49$5.13M-0.17619,697 shs15,263 shsDNAGinkgo Bioworks$12.660.0%$8.34$5.00▼$16.85$744.53M1.481.43 million shs1.40 million shsSLSSELLAS Life Sciences Group$2.18+2.6%$1.71$0.77▼$2.27$216.52M2.311.72 million shs1.40 million shsTLRYTilray Brands$0.53+9.4%$0.43$0.35▼$2.15$542.20M1.8229.90 million shs43.04 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group+3.90%-3.61%-7.25%+27.98%-75.70%DNAGinkgo Bioworks-0.12%+31.93%+69.14%+128.51%-5.36%SLSSELLAS Life Sciences Group+2.59%+7.14%+32.62%+109.13%+90.79%TLRYTilray Brands+9.44%+28.76%+32.75%-10.33%-69.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPMAptorum Group0.6316 of 5 stars0.03.00.00.01.01.70.6DNAGinkgo Bioworks1.1417 of 5 stars0.82.00.00.03.22.51.3SLSSELLAS Life Sciences Group0.1667 of 5 stars0.01.00.00.00.61.70.6TLRYTilray Brands1.8132 of 5 stars3.11.00.00.02.50.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 0.00N/AN/AN/ADNAGinkgo Bioworks 1.67Reduce$5.77-54.43% DownsideSLSSELLAS Life Sciences Group 0.00N/AN/AN/ATLRYTilray Brands 2.25Hold$1.92260.95% UpsideCurrent Analyst Ratings BreakdownLatest APM, DNA, SLS, and TLRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025TLRYTilray BrandsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/9/2025TLRYTilray BrandsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K11.94N/AN/A$2.20 per share0.44DNAGinkgo Bioworks$227.04M3.26N/AN/A$13.17 per share0.96SLSSELLAS Life Sciences Group$1M217.02N/AN/A$0.13 per share16.73TLRYTilray Brands$788.94M0.68N/AN/A$4.14 per share0.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$4.27MN/A0.00∞N/AN/AN/AN/A7/30/2025 (Estimated)DNAGinkgo Bioworks-$547.03M-$9.16N/AN/AN/A-198.84%-52.35%-27.14%8/14/2025 (Estimated)SLSSELLAS Life Sciences Group-$30.88M-$0.38N/AN/AN/AN/A-193.67%-113.02%8/12/2025 (Estimated)TLRYTilray Brands-$244.98M-$1.05N/AN/AN/A-113.85%-7.40%-6.02%8/4/2025 (Estimated)Latest APM, DNA, SLS, and TLRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SLSSELLAS Life Sciences Group-$0.1067-$0.07+$0.0367-$0.07N/AN/A5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 million4/8/2025Q3 2025TLRYTilray Brands-$0.04-$0.10-$0.06-$0.87$213.38 million$185.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum GroupN/A0.220.22DNAGinkgo BioworksN/A4.884.88SLSSELLAS Life Sciences GroupN/A4.644.64TLRYTilray Brands0.122.621.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%DNAGinkgo Bioworks78.63%SLSSELLAS Life Sciences Group17.38%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%DNAGinkgo Bioworks9.72%SLSSELLAS Life Sciences Group1.40%TLRYTilray Brands0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group305.35 million1.93 millionNot OptionableDNAGinkgo Bioworks64058.53 million52.84 millionOptionableSLSSELLAS Life Sciences Group1099.78 million98.38 millionNot OptionableTLRYTilray Brands2,6501.01 billion1.00 billionOptionableAPM, DNA, SLS, and TLRY HeadlinesRecent News About These CompaniesTilray Brands (NASDAQ:TLRY) Stock Price Up 9.4% - Still a Buy?July 4 at 12:13 PM | marketbeat.comHere’s why the Tilray Brands stock price has implodedJuly 3 at 5:07 PM | invezz.comIStock Traders Buy Large Volume of Tilray Brands Call Options (NASDAQ:TLRY)July 3 at 2:09 PM | marketbeat.comCannabis Stocks To Keep An Eye On - July 3rdJuly 3 at 1:46 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading 4.1% Higher - Here's WhyJuly 2 at 1:37 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Stock Price Down 1.3% - Should You Sell?July 1 at 3:40 PM | marketbeat.comBeers, Live Music, Hot Dogs and Fireworks: Everything You Need for an Epic 4th Of July CelebrationJuly 1 at 8:19 AM | financialpost.comFBreckenridge Distillery Unveils Limited-Edition Collectors Art Series Collaboration with Renowned Artist Miles TolandJuly 1 at 7:04 AM | financialpost.comFBreckenridge Distillery Unveils Limited-Edition Collectors Art Series Collaboration with Renowned Artist Miles TolandJuly 1 at 7:00 AM | globenewswire.comTLRY - Tilray Brands Inc News - MorningstarJune 28, 2025 | morningstar.comMTilray Brands, Inc. (TLRY) Stock Declines While Market Improves: Some Information for InvestorsJune 27, 2025 | zacks.comTilray Brands (NASDAQ:TLRY) Shares Up 3.9% - Should You Buy?June 26, 2025 | marketbeat.comTilray Brands (NasdaqGS:TLRY) Advances Medical Cannabis Research With New Bioavailability StudyJune 26, 2025 | finance.yahoo.comTilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD FormulationsJune 26, 2025 | finance.yahoo.comMontauk Brewing Celebrates 13 Years of Brewing with Faherty Collaboration and Beach Clean Up with the Surfrider FoundationJune 26, 2025 | globenewswire.comTLRY Stock - Tilray Brands Inc Stock Price Quote - XTSE - MorningstarJune 26, 2025 | morningstar.comMHere Is A List Of 3 Canadian Marijuana Stocks To Watch 2025June 25, 2025 | marijuanastocks.comMTilray Medical Launches “Good Supply” Cannabis Brand in GermanyJune 25, 2025 | insidermonkey.comTilray Medical Receives Italy’s First Authorization from the Ministry of Health to Distribute Medical Cannabis Flower for Therapeutic UseJune 24, 2025 | finance.yahoo.comTilray sets medical cannabis milestone in ItalyJune 24, 2025 | msn.comTilray Brands Stock Price, Quotes and Forecasts | NASDAQ:TLRY - BenzingaJune 24, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPM, DNA, SLS, and TLRY Company DescriptionsAptorum Group NASDAQ:APM$0.96 +0.04 (+4.18%) Closing price 07/3/2025 03:01 PM EasternExtended Trading$0.94 -0.02 (-1.98%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Ginkgo Bioworks NYSE:DNA$12.66 -0.01 (-0.04%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$12.63 -0.03 (-0.23%) As of 07/3/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.SELLAS Life Sciences Group NASDAQ:SLS$2.17 +0.06 (+2.59%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$2.17 0.00 (-0.18%) As of 07/3/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Tilray Brands NASDAQ:TLRY$0.53 +0.05 (+9.44%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$0.54 +0.00 (+0.75%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
